Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Accured Expenses (2020 - 2025)

RxSight (RXST) has disclosed Change in Accured Expenses for 6 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 51.26% year-over-year to $1.7 million, compared with a TTM value of -$1.9 million through Dec 2025, down 131.95%, and an annual FY2025 reading of -$1.9 million, down 131.95% over the prior year.
  • Change in Accured Expenses was $1.7 million for Q4 2025 at RxSight, up from $1.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.7 million in Q3 2024 and bottomed at -$6.2 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $740200.0, with a median of $1.5 million recorded in 2023.
  • The sharpest move saw Change in Accured Expenses surged 421.04% in 2021, then crashed 191.16% in 2022.
  • Year by year, Change in Accured Expenses stood at $1.6 million in 2021, then skyrocketed by 51.44% to $2.4 million in 2022, then decreased by 9.52% to $2.2 million in 2023, then surged by 58.72% to $3.5 million in 2024, then crashed by 51.26% to $1.7 million in 2025.
  • Business Quant data shows Change in Accured Expenses for RXST at $1.7 million in Q4 2025, $1.6 million in Q3 2025, and $1.0 million in Q2 2025.